**Chapter 10**

*Type 2 Diabetes - From Pathophysiology to Cyber Systems*

Kramer MK, Kahn S, Ma Y, Edelstein S,

medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006;29:1997-2002. https://doi.org/10.2337/dc06-0454.

[185] McEwen LN, Casagrande SS, Kuo S, Herman WH. Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost? Curr Diab Rep 2017;17. https://doi. org/10.1007/s11892-017-0893-0.

[186] Alvino VV, Fernández-Jiménez R, Rodriguez-Arabaolaza I, Slater S, Mangialardi G, Avolio E, et al.

Transplantation of Allogeneic Pericytes Improves Myocardial Vascularization and Reduces Interstitial Fibrosis in a Swine Model of Reperfused Acute Myocardial Infarction. J Am Heart Assoc 2018;7. https://doi.org/10.1161/

[187] Shin L, Peterson DA. Impaired Therapeutic Capacity of Autologous Stem Cells in a Model of Type 2 Diabetes. Stem Cells Transl Med 2012;1:125-35. https://doi.org/10.5966/

[188] Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev 2016;1:2. https://doi. org/10.1186/s41073-016-0007-6.

JAHA.117.006727.

sctm.2012-0031.

[184] Walker EA, Molitch M,

et al. Adherence to preventive

**248**
